Literature DB >> 16254978

Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.

Guillaume S Carpentier1, Maxime J J Fleury, Antoine Touzé, Jean-Rémy Sadeyen, Sylvie Tourne, Pierre-Yves Sizaret, Pierre Coursaget.   

Abstract

The aim of this study was to further characterize the conformational neutralizing epitopes present on the surface-exposed FG loop of human papillomavirus (HPV) type 16 L1 major capsid protein. We have generated previously two chimeric L1 proteins by insertion of a foreign peptide encoding an epitope of the hepatitis B core (HBc) antigen within the FG loop. In addition, three other chimeric L1 proteins were obtained by replacing three different FG loop sequences by the HBc motif and three others by point mutations. All these chimeric L1 proteins retained the ability to self-assemble into virus-like particles (VLPs), with the exception of the mutant with substitution of the L1 sequence 274-279 by the HBc motif. The eight chimeric VLPs were then analyzed for differential reactivity with a set of six HPV-16 and HPV-31 monoclonal antibodies that bound to conformational and linear epitopes. The binding patterns of these monoclonal antibodies confirmed that the FG loop contained or contributed to neutralizing conformational epitopes. The results obtained suggested that the H31.F7 antibody, an anti-HPV-31 cross-reacting and neutralizing antibody, recognized a conformational epitope situated before the 266-271 sequence. In addition, H16.E70 neutralizing antibody reactivity was reduced with L1 VLPs with an Asn to Ala point mutation at position 270, suggesting that Asn is a part of the epitope recognized by this antibody. This study contributes to the understanding of the antigenic structure of HPV-16 and -31 L1 proteins by confirming that the FG loop contributes to neutralizing epitopes and suggesting the existence of both type-specific and cross-reactive conformational epitopes within the FG loop. Copyright (c) 2005 Wiley-Liss, inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254978     DOI: 10.1002/jmv.20492

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  11 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

3.  Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy.

Authors:  Maxime J J Fleury; Antoine Touzé; Pierre Coursaget
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.695

4.  Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.

Authors:  Sara L Bissett; Anna Godi; Maxime J J Fleury; Antoine Touze; Clementina Cocuzza; Simon Beddows
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

5.  Genetic variation within the human papillomavirus type 16 genome is associated with oropharyngeal cancer prognosis.

Authors:  K A Lang Kuhs; D L Faden; L Chen; D K Smith; M Pinheiro; C B Wood; S Davis; M Yeager; J F Boland; M Cullen; M Steinberg; S Bass; X Wang; P Liu; M Mehrad; T Tucker; J S Lewis; R L Ferris; L Mirabello
Journal:  Ann Oncol       Date:  2022-03-16       Impact factor: 51.769

6.  Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.

Authors:  Ariana Harari; Zigui Chen; Ana Cecilia Rodríguez; Allan Hildesheim; Carolina Porras; Rolando Herrero; Sholom Wacholder; Orestis A Panagiotou; Brian Befano; Robert D Burk; Mark Schiffman
Journal:  J Infect Dis       Date:  2015-10-30       Impact factor: 5.226

7.  Identification of the neutralizing epitopes of Merkel cell polyomavirus major capsid protein within the BC and EF surface loops.

Authors:  Maxime J J Fleury; Jérôme T J Nicol; Mahtab Samimi; Françoise Arnold; Raphael Cazal; Raphaelle Ballaire; Olivier Mercey; Hélène Gonneville; Nicolas Combelas; Jean-Francois Vautherot; Thierry Moreau; Gérard Lorette; Pierre Coursaget; Antoine Touzé
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

8.  The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies.

Authors:  Sara L Bissett; Anna Godi; Simon Beddows
Journal:  Sci Rep       Date:  2016-12-22       Impact factor: 4.379

9.  Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.

Authors:  Amina I Ahmed; Sara L Bissett; Simon Beddows
Journal:  Infect Genet Evol       Date:  2013-05-27       Impact factor: 3.342

10.  Evidences of Changes in Surface Electrostatic Charge Distribution during Stabilization of HPV16 Virus-Like Particles.

Authors:  Juan F Vega; Ernesto Vicente-Alique; Rafael Núñez-Ramírez; Yang Wang; Javier Martínez-Salazar
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.